SMT202200054T1 - Composti di-nucleotidici ciclici per il trattamento del cancro - Google Patents

Composti di-nucleotidici ciclici per il trattamento del cancro

Info

Publication number: SMT202200054T1
Authority: SM; San Marino
Prior art keywords: nucleotides; cancer; cyclic; compounds; treatment
Prior art date: 2017-02-17

Application number

SM20220054T

Other languages

English (en)

Inventor

Frank Fang

Ming-Hong Hao

Atsushi Endo

Dae-Shik Kim

Hyeong-Wook Choi

Xingfeng Bao

Kuan-Chun Huang

Original Assignee

Eisai R&D Man Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-02-17

Filing date

2018-02-17

Publication date

2022-03-21

2018-02-17 Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd

2022-03-21 Publication of SMT202200054T1 publication Critical patent/SMT202200054T1/it

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6587—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having two phosphorus atoms as ring hetero atoms in the same ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Peptides Or Proteins (AREA)

SM20220054T 2017-02-17 2018-02-17 Composti di-nucleotidici ciclici per il trattamento del cancro SMT202200054T1 (it)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201762460562P	2017-02-17	2017-02-17
US201762479169P	2017-03-30	2017-03-30
US201762551645P	2017-08-29	2017-08-29
US201762551647P	2017-08-29	2017-08-29
US201762551668P	2017-08-29	2017-08-29
PCT/US2018/018556 WO2018152450A1 (en)	2017-02-17	2018-02-17	Cyclic di-nucleotides compounds for the treatment of cancer
EP18708032.0A EP3582853B1 (en)	2017-02-17	2018-02-17	Cyclic di-nucleotides compounds for the treatment of cancer

Publications (1)

Publication Number	Publication Date
SMT202200054T1 true SMT202200054T1 (it)	2022-03-21

Family

ID=61521844

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM20220054T SMT202200054T1 (it)	2017-02-17	2018-02-17	Composti di-nucleotidici ciclici per il trattamento del cancro

Country Status (32)

Country	Link
US (4)	US20200055883A1 (it)
EP (3)	EP3582854A1 (it)
JP (2)	JP6672532B2 (it)
KR (1)	KR102645790B1 (it)
CN (3)	CN110461416B (it)
AU (1)	AU2018221170B2 (it)
CA (1)	CA3053932A1 (it)
CL (1)	CL2019002304A1 (it)
CO (1)	CO2019008783A2 (it)
CY (1)	CY1126855T1 (it)
DK (1)	DK3582853T3 (it)
ES (1)	ES2906299T3 (it)
HR (1)	HRP20220110T1 (it)
HU (1)	HUE057665T2 (it)
IL (1)	IL268721B (it)
JO (1)	JOP20190194B1 (it)
LT (1)	LT3582853T (it)
MA (1)	MA47501A (it)
MD (1)	MD3582853T2 (it)
MX (1)	MX394380B (it)
PE (1)	PE20191686A1 (it)
PH (1)	PH12019501914B1 (it)
PL (1)	PL3582853T3 (it)
PT (1)	PT3582853T (it)
RS (1)	RS62842B1 (it)
SG (1)	SG11201907496RA (it)
SI (1)	SI3582853T1 (it)
SM (1)	SMT202200054T1 (it)
TW (1)	TWI766948B (it)
UA (1)	UA125310C2 (it)
WO (2)	WO2018152450A1 (it)
ZA (1)	ZA201906111B (it)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JOP20170192A1 (ar)	2016-12-01	2019-01-30	Takeda Pharmaceuticals Co	داي نوكليوتيد حلقي
PT3570844T (pt)	2017-01-20	2023-11-15	Arcus Biosciences Inc	Azolopirimidina para o tratamento de doenças relacionadas com o cancro
PL3601233T3 (pl)	2017-03-27	2025-01-07	HYDRO-QUéBEC	Sole do zastosowania w kompozycjach elektrolitowych lub jako dodatki do elektrod
WO2019084060A1 (en)	2017-10-24	2019-05-02	Silverback Therapeutics, Inc.	CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
SG11202004113VA (en)	2017-11-10	2020-06-29	Takeda Pharmaceuticals Co	Sting modulator compounds, and methods of making and using
US10966999B2 (en)	2017-12-20	2021-04-06	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US11203610B2 (en)	2017-12-20	2021-12-21	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
AU2019222747B2 (en)	2018-02-16	2024-09-05	Arcus Biosciences, Inc.	Dosing with an azolopyrimidine compound
TWI833744B (zh)	2018-04-06	2024-03-01	捷克科學院有機化學與生物化學研究所	3'3'-環二核苷酸
TWI818007B (zh)	2018-04-06	2023-10-11	捷克科學院有機化學與生物化學研究所	2'3'-環二核苷酸
MX2020012964A (es)	2018-06-01	2021-02-16	Eisai R&D Man Co Ltd	Metodos para el tratamiento de cancer de vejiga.
JP6767589B1 (ja) *	2018-08-16	2020-10-14	エーザイ・アール・アンド・ディー・マネジメント株式会社	化合物の塩及びそれらの結晶
AU2019339344A1 (en)	2018-09-12	2021-03-18	Silverback Therapeutics, Inc.	Compositions for the treatment of disease with immune stimulatory conjugates
WO2020135715A1 (zh) *	2018-12-29	2020-07-02	上海济煜医药科技有限公司	作为肿瘤免疫类的化合物及其应用
AU2020267486A1 (en)	2019-05-09	2021-11-11	Aligos Therapeutics, Inc.	Modified cyclic dinucleoside compounds as STING modulators
US11453681B2 (en) *	2019-05-23	2022-09-27	Gilead Sciences, Inc.	Substituted eneoxindoles and uses thereof
BR112021026876A2 (pt) *	2019-07-01	2022-02-22	Eisai R&D Man Co Ltd	Métodos para o tratamento do câncer
WO2021067644A1 (en)	2019-10-01	2021-04-08	Silverback Therapeutics, Inc.	Combination therapy with immune stimulatory conjugates
JP2022177332A (ja) *	2019-10-24	2022-12-01	日東電工株式会社	オリゴヌクレオチドを製造する方法
WO2021168274A1 (en)	2020-02-21	2021-08-26	Silverback Therapeutics, Inc.	Nectin-4 antibody conjugates and uses thereof
WO2021206158A1 (ja)	2020-04-10	2021-10-14	小野薬品工業株式会社	がん治療方法
US20230210968A1 (en)	2020-06-11	2023-07-06	Massachusetts Institute Of Technology	Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy
CA3183993A1 (en)	2020-07-01	2022-01-06	Peter R. Baum	Anti-asgr1 antibody conjugates and uses thereof
CN111909223A (zh) *	2020-07-17	2020-11-10	清华大学	环二核苷酸共价修饰物及其制备方法和应用
WO2022079175A1 (en)	2020-10-14	2022-04-21	Boehringer Ingelheim International Gmbh	Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
JP7397996B2 (ja)	2020-11-09	2023-12-13	武田薬品工業株式会社	抗体薬物コンジュゲート
WO2024182569A2 (en)	2023-02-28	2024-09-06	Eisai R&D Management Co., Ltd.	Anti-psma antibodies, conjugates, and methods of use

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2257704B (en)	1991-07-18	1995-03-01	Erba Carlo Spa	Cyclic oligonucleotides phosphorothioates
AU2005222626B2 (en)	2004-03-15	2010-05-20	Karagen Pharmaceuticals, Inc.	A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
US7592326B2 (en)	2004-03-15	2009-09-22	Karaolis David K R	Method for stimulating the immune, inflammatory or neuroprotective response
US8076303B2 (en)	2005-12-13	2011-12-13	Spring Bank Pharmaceuticals, Inc.	Nucleotide and oligonucleotide prodrugs
GB0607950D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
WO2009133560A1 (en)	2008-04-29	2009-11-05	Smart Assays	Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
CN102199183B (zh)	2010-03-26	2013-12-18	北京大学	环二鸟苷酸及其类似物和制备方法
AU2013271375B2 (en) *	2012-06-08	2018-03-22	Aduro Biotech, Inc.	Compositions and methods for cancer immunotherapy
EP2931738B1 (en) *	2012-12-13	2019-02-06	Aduro Biotech, Inc.	Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
CU24376B1 (es)	2013-04-29	2018-12-05	Memorial Sloan Kettering Cancer Center	ANÁLOGOS DE LA GMP-AMP CÍCLICO (cGAMP) ACTIVOS COMO MODULADORES DE LA GMP-AMP CÍCLICO SINTASA (cGAS) Y COMPOSICIONES FARMACÉUTICAS DEL MISMO
ES2822584T3 (es)	2013-05-03	2021-05-04	Univ California	Inducción de dinucleótidos cíclicos del interferón tipo I
US9549944B2 (en)	2013-05-18	2017-01-24	Aduro Biotech, Inc.	Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
SI2996473T1 (sl)	2013-05-18	2019-12-31	Aduro Biotech, Inc.	Sestavki in postopki za aktiviranje signaliziranja, odvisnega od "stimulator interferonskih genov"
JP2016538344A (ja)	2013-11-19	2016-12-08	ザ・ユニバーシティ・オブ・シカゴＴｈｅＵｎｉｖｅｒｓｉｔｙＯｆＣｈｉｃａｇｏ	癌処置としてのｓｔｉｎｇアゴニストの使用
US10092644B2 (en)	2013-11-22	2018-10-09	Brock University	Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
EA029856B9 (ru)	2014-06-04	2018-08-31	Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед	Циклические динуклеотиды в качестве модуляторов стимулятора генов интерферона (sting)
WO2016079899A1 (ja) *	2014-11-20	2016-05-26	国立研究開発法人医薬基盤・健康・栄養研究所	異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
PT3233882T (pt)	2014-12-16	2020-01-21	Kayla Therapeutics	Dinucleótidos cíclicos fluorados para a indução de citocinas
US20170340658A1 (en)	2014-12-16	2017-11-30	Invivogen	Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
EP3233089A4 (en)	2014-12-17	2018-11-14	Lipogen LLC	Method of treating cancer with cgamp or cgasmp
GB201501462D0 (en)	2015-01-29	2015-03-18	Glaxosmithkline Ip Dev Ltd	Novel compounds
BR112017018908A2 (pt) *	2015-03-10	2018-04-17	Aduro Biotech, Inc.	composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon
TW201717968A (zh)	2015-07-14	2017-06-01	春季銀行製藥公司	誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物
WO2017011920A1 (en)	2015-07-22	2017-01-26	The Royal Institution For The Advancement Of Learning/Mcgill University	Compounds and uses thereof in the treatment of cancers and other medical conditions
MA42608A (fr)	2015-08-13	2018-06-20	Merck Sharp & Dohme	Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron)
US9809597B2 (en)	2015-08-20	2017-11-07	The Board Of Trustees Of The Leland Stanford Junior University	Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy
WO2017040670A1 (en)	2015-09-01	2017-03-09	Ifm Therapeutics, Inc	Immune cells having increased immunity or resistance to an immunosuppressive cytokine and use of the same
AU2016343993A1 (en)	2015-10-28	2018-05-10	Aduro Biotech, Inc.	Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
CN107849084B (zh)	2015-12-03	2021-09-14	葛兰素史密斯克莱知识产权发展有限公司	作为sting调节剂的环状嘌呤二核苷酸
JP6801956B2 (ja)	2015-12-04	2020-12-16	株式会社エクセディ	モータサイクル用クラッチ装置
SG11201805888SA (en)	2016-01-11	2018-08-30	Innate Tumor Immunity Inc	Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
WO2017123657A1 (en)	2016-01-11	2017-07-20	Gary Glick	Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
IL280430B2 (en)	2016-03-18	2023-11-01	Univ Texas	Cyclic dinucleotide compounds and methods of use
BR112018070602A2 (pt)	2016-04-07	2019-02-05	Glaxosmithkline Ip Dev Ltd	composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
US10537590B2 (en)	2016-09-30	2020-01-21	Boehringer Ingelheim International Gmbh	Cyclic dinucleotide compounds
JOP20170188A1 (ar)	2016-11-25	2019-01-30	Janssen Biotech Inc	ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
WO2018140831A2 (en)	2017-01-27	2018-08-02	Silverback Therapeutics, Inc.	Tumor targeting conjugates and methods of use thereof
WO2018198084A1 (en)	2017-04-27	2018-11-01	Lupin Limited	Cyclic di-nucleotide compounds with tricyclic nucleobases
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo

2018
- 2018-02-16 US US16/486,954 patent/US20200055883A1/en not_active Abandoned
- 2018-02-17 ES ES18708032T patent/ES2906299T3/es active Active
- 2018-02-17 EP EP18709835.5A patent/EP3582854A1/en not_active Withdrawn
- 2018-02-17 JP JP2019544817A patent/JP6672532B2/ja active Active
- 2018-02-17 EP EP21208462.8A patent/EP4008403A1/en not_active Withdrawn
- 2018-02-17 DK DK18708032.0T patent/DK3582853T3/da active
- 2018-02-17 LT LTEPPCT/US2018/018556T patent/LT3582853T/lt unknown
- 2018-02-17 AU AU2018221170A patent/AU2018221170B2/en active Active
- 2018-02-17 MD MDE20200009T patent/MD3582853T2/ro unknown
- 2018-02-17 HR HRP20220110TT patent/HRP20220110T1/hr unknown
- 2018-02-17 SG SG11201907496RA patent/SG11201907496RA/en unknown
- 2018-02-17 UA UAA201909860A patent/UA125310C2/uk unknown
- 2018-02-17 PE PE2019001715A patent/PE20191686A1/es unknown
- 2018-02-17 KR KR1020197027073A patent/KR102645790B1/ko active Active
- 2018-02-17 MX MX2019009796A patent/MX394380B/es unknown
- 2018-02-17 JO JOP/2019/0194A patent/JOP20190194B1/ar active
- 2018-02-17 WO PCT/US2018/018556 patent/WO2018152450A1/en active Application Filing
- 2018-02-17 RS RS20220079A patent/RS62842B1/sr unknown
- 2018-02-17 EP EP18708032.0A patent/EP3582853B1/en active Active
- 2018-02-17 CN CN201880021349.XA patent/CN110461416B/zh active Active
- 2018-02-17 MA MA047501A patent/MA47501A/fr unknown
- 2018-02-17 PL PL18708032T patent/PL3582853T3/pl unknown
- 2018-02-17 PH PH1/2019/501914A patent/PH12019501914B1/en unknown
- 2018-02-17 PT PT187080320T patent/PT3582853T/pt unknown
- 2018-02-17 WO PCT/US2018/018561 patent/WO2018152453A1/en unknown
- 2018-02-17 JP JP2019544725A patent/JP2020510638A/ja active Pending
- 2018-02-17 SI SI201830553T patent/SI3582853T1/sl unknown
- 2018-02-17 CA CA3053932A patent/CA3053932A1/en active Pending
- 2018-02-17 CN CN202410024195.7A patent/CN117866030A/zh active Pending
- 2018-02-17 CN CN201880025317.7A patent/CN110536719A/zh active Pending
- 2018-02-17 US US15/898,533 patent/US10246480B2/en active Active
- 2018-02-17 SM SM20220054T patent/SMT202200054T1/it unknown
- 2018-02-17 HU HUE18708032A patent/HUE057665T2/hu unknown
- 2018-02-21 TW TW107105846A patent/TWI766948B/zh active
2019
- 2019-02-15 US US16/277,522 patent/US10618930B2/en active Active
- 2019-08-13 CO CONC2019/0008783A patent/CO2019008783A2/es unknown
- 2019-08-14 CL CL2019002304A patent/CL2019002304A1/es unknown
- 2019-08-15 IL IL268721A patent/IL268721B/en unknown
- 2019-09-16 ZA ZA2019/06111A patent/ZA201906111B/en unknown
2020
- 2020-02-04 US US16/781,352 patent/US11339188B2/en active Active
2022
- 2022-01-26 CY CY20221100065T patent/CY1126855T1/el unknown

Also Published As

Publication number	Publication date
EP3582853B1 (en)	2021-11-17
EP4008403A1 (en)	2022-06-08
KR20190120266A (ko)	2019-10-23
PH12019501914A1 (en)	2020-03-16
SG11201907496RA (en)	2019-09-27
IL268721A (en)	2019-10-31
UA125310C2 (uk)	2022-02-16
WO2018152450A1 (en)	2018-08-23
US20190345192A1 (en)	2019-11-14
ES2906299T3 (es)	2022-04-18
CA3053932A1 (en)	2018-08-23
EP3582853A1 (en)	2019-12-25
CN110461416B (zh)	2024-01-26
KR102645790B1 (ko)	2024-03-11
PE20191686A1 (es)	2019-11-19
ZA201906111B (en)	2023-12-20
WO2018152453A1 (en)	2018-08-23
MD3582853T2 (ro)	2022-04-30
MA47501A (fr)	2019-12-25
EP3582854A1 (en)	2019-12-25
PH12019501914B1 (en)	2024-02-21
CY1126855T1 (el)	2024-12-13
AU2018221170B2 (en)	2024-03-28
US20180237468A1 (en)	2018-08-23
CL2019002304A1 (es)	2020-01-10
AU2018221170A1 (en)	2019-10-10
CN110461416A (zh)	2019-11-15
JP2020510638A (ja)	2020-04-09
TW201842918A (zh)	2018-12-16
HRP20220110T1 (hr)	2022-04-15
RS62842B1 (sr)	2022-02-28
DK3582853T3 (da)	2022-02-07
SI3582853T1 (sl)	2022-04-29
TWI766948B (zh)	2022-06-11
CO2019008783A2 (es)	2020-01-17
MX394380B (es)	2025-03-24
JOP20190194A1 (ar)	2019-08-15
US11339188B2 (en)	2022-05-24
LT3582853T (lt)	2022-02-10
MX2019009796A (es)	2019-10-22
CN110536719A (zh)	2019-12-03
RU2019129127A3 (it)	2021-06-08
PL3582853T3 (pl)	2022-02-21
JOP20190194B1 (ar)	2023-09-17
BR112019017084A2 (pt)	2020-04-14
US10246480B2 (en)	2019-04-02
IL268721B (en)	2022-04-01
US20200299321A1 (en)	2020-09-24
HUE057665T2 (hu)	2022-06-28
US10618930B2 (en)	2020-04-14
US20200055883A1 (en)	2020-02-20
PT3582853T (pt)	2022-02-02
CN117866030A (zh)	2024-04-12
JP6672532B2 (ja)	2020-03-25
RU2019129127A (ru)	2021-03-17
JP2020508304A (ja)	2020-03-19

Publication	Publication Date	Title
IL268721B (en)	2022-04-01	Cyclic dinucleotide compounds for cancer therapy
HK1247202A1 (zh)	2018-09-21	用於治療癌症的化合物
ZA201905902B (en)	2021-05-26	2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
IL252935A0 (en)	2017-08-31	Cyclic dinucleotides used to treat cancer among others
LT3109223T (lt)	2018-11-12	Junginys, skirtas karbamido turinčių trąšų apdorojimui
IL259996A (en)	2018-07-31	Combinations for cancer treatment
IL263835A (en)	2019-02-03	Exosome-guided treatment of cancer
HK1252245A1 (zh)	2019-05-24	用於治療癌症的核苷酸
IL261278A (en)	2018-10-31	Pharmaceutical compositions for the treatment of cancer
IL275525A (en)	2020-08-31	A pharmaceutical preparation for the treatment of cancer
ZA201901578B (en)	2022-04-28	Combinations including abx196 for the treatment of cancer
IL274748A (en)	2020-07-30	Improved cancer treatment
PL3630754T3 (pl)	2022-10-24	Związki izoindolinoacetylenowe do leczenia nowotworu
IL255167A0 (en)	2017-12-31	Compounds for the treatment of cancer
EP3242681B8 (en)	2020-11-25	Novel compounds for the treatment of cancer
PT3580211T (pt)	2021-02-01	2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro
ZA201704589B (en)	2019-02-27	Compounds for the treatment of cancer
GB201713936D0 (en)	2017-10-18	Pharmaceutical combinations for the treatment of cancer
GB201704287D0 (en)	2017-05-03	Treatment of cancer
GB201703857D0 (en)	2017-04-26	Treatment of cancer
GB201702565D0 (en)	2017-04-05	Treatment of cancer
GB201622214D0 (en)	2017-02-08	treatment of cancer
GB201604621D0 (en)	2016-05-04	Treatment of cancer
GB201604293D0 (en)	2016-04-27	Treatment of cancer
GB201507937D0 (en)	2015-06-24	Compounds for treatment of pancreatic cancer